Dexcom (DXCM) FY2025 10-K Annual Report
Dexcom (DXCM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Dexcom FY2025 10-K Analysis
Business Overview
- • Core business: Design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management
- • New product launched: Stelo, first over-the-counter glucose biosensor for prediabetes and Type 2 diabetes adults not using insulin (U.S. launch Aug 2024)
Management Discussion & Analysis
- • Revenue $4,662M, up 16% YoY from $4,033M driven by 600K-700K net customer additions
- • Operating margin 20.0% vs 14.9%, operating income $911.8M up 52% YoY from $600.0M
Risk Factors
- • Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs
- • Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards
Dexcom FY2025 Key Financial MetricsXBRL
Revenue
$4.7B
▲ +15.6% YoY
Net Income
$836M
▲ +45.1% YoY
Gross Margin
60.1%
▼ -36bp YoY
Operating Margin
19.6%
▲ +468bp YoY
Net Margin
17.9%
▲ +365bp YoY
ROE
30.5%
▲ +305bp YoY
Total Assets
$6.3B
▼ -2.2% YoY
EPS (Diluted)
$2.09
▲ +47.2% YoY
Operating Cash Flow
$1.4B
▲ +45.6% YoY
Source: XBRL data from Dexcom FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Dexcom
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.